E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD) |
|
E.1.1.1 | Medical condition in easily understood language |
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD) is an inflammatory demyelinating condition of the central nervous system (CNS). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10012302 |
E.1.2 | Term | Demyelinating disorders NEC |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the efficacy of rozanolixizumab for treatment of participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD) |
|
E.2.2 | Secondary objectives of the trial |
Assess the safety and tolerability of rozanolixizumab in participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Participants must be ≥18 to ≤89 years of age, at the time of signing the informed consent -Confirmed diagnosis of MOG-AD consistent with published diagnostic criteria for MOG-AD - Participant has history of relapsing MOG-AD with at least 1 documented relapse over the last 12 months and a documented positive serum MOG Ab test using a cellbased assay (CBA) within 6 months prior to randomization - Participant must be clinically stable at the time of the Screening Visit and during the Screening Period
|
|
E.4 | Principal exclusion criteria |
- Participant has been diagnosed with a neurological autoimmune disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant - Participant has a clinically important active infection (including unresolved or not adequately treated infection) as assessed by the investigator, including participants with a serious infection within 6 weeks prior to the first dose of the investigational medicinal product (IMP) - Participant has a current or medical history of primary immunodeficiency - Participant tests positive for aquaporin-4 antibodies at screening - Participant has a serum total IgG level ≤5.5g/L |
|
E.5 End points |
E.5.1 | Primary end point(s) |
For Part A: 1. Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment Period For Part B: 2. Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment Period 3. Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment Period |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Baseline (Week 1) to EDB/EWD Visit ((until a confirmed relapse or up to approximately 132 weeks) 2, 3: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52) |
|
E.5.2 | Secondary end point(s) |
For Part A 1. Change from Baseline in Low-Contrast Monocular Visual Acuity (Worst Affected Eye) measured by low-contrast Landolt C Broken Rings Chart at the EDB/EWD Visit 2. Disability as assessed by Expanded Disability Status Scale (EDSS) scores at the end of the EDB/EWD Visit (with confirmation at 3 months) 3. Number of MOG-AD related inpatient hospitalizations during the DB Treatment Period 4. Incidence of treatment-emergent adverse events (TEAEs) during DB Treatment Period For Part B 5. Independently centrally adjudicated annualized relapse rate (ARR) during the DB and OLE Treatment Period |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. From Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks) 2. Baseline (Week 1), EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks) 3, 4: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks) 5: Baseline (Week 1) through EOS/EWD Visit´(up to OLE Week 52) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability and immunogenicity |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
MOG001 consists of a Double-Blind (Part A) and an Open-Label Extension Study Period (Part B). |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 34 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Switzerland |
Ukraine |
Taiwan |
Australia |
Brazil |
Japan |
Korea, Republic of |
Mexico |
United Kingdom |
United States |
Belgium |
Czechia |
France |
Germany |
Italy |
Portugal |
Spain |
Sweden |
Türkiye |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 3 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 3 |